Pilot to validate in vivo 2-HG MR spectroscopy in low grade gliomas

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON24067

Enrollment

Registered

2018-01-12

Start date

2018-03-01

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

2-HG MRI Spectroscopy Low grade glioma IDH

Interventions

MR spectroscopy for 2-HG.

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a low grade glioma ≥ 18 years that are planned to undergo surgery

Exclusion criteria

Exclusion criteria: - Patients with recent cerebral radiotherapy or operation (<3 months). - Age <18 years. - General contra-indications for MRI (non compatible material , pregnancy or claustrophobia)

Design outcomes

Primary

Measure	Time frame
Primary endpoint is the correlation between the presence of the IDH mutation and a 2-HG peak on MR spectroscopy (binary variables). Also primary endpoint is the correlation between the concentration of 2-HG on in vivo MR spectroscopy and ex vivo in the tissue, uitgedrukt in mmol/mg (continue variabelen).	—

Contacts

Public ContactA. Hoorn, van der

Department of radiology (EB44), University Medical Center Groningen

a.van.der.hoorn@umcg.nl+31503616161

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)